As SK Capital Partners completes its acquisition of Apotex, generics industry veteran Allan Oberman has been named as the new president and CEO of the Canadian giant, replacing Jeff Watson who will remain on the company’s board.
Fresh leadership has been installed at Apotex, as the Canadian generics giant announced the completion of its acquisition by funds advised by SK Capital Partners.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
